Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 109

1.

Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.

Prorok PC, Miller AB.

Ann Intern Med. 2018 Apr 17;168(8):605-606. doi: 10.7326/L17-0735. No abstract available.

PMID:
29677259
2.

Overall and Multiphasic Findings of the Prostate, Lung, Colorectal and Ovarian (PLCO) Randomized Cancer Screening Trial.

Prorok PC, Wright P, Riley TR, Kramer BS, Berg CD, Gohagan JK.

Rev Recent Clin Trials. 2018 Apr 9. doi: 10.2174/1574887113666180409153059. [Epub ahead of print]

PMID:
29629665
3.

Editorial: Challenges in Quantifying Overdiagnosis.

Baker SG, Prorok PC, Kramer BS.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx064. No abstract available.

PMID:
29117354
4.

Prostate Cancer Screening.

Pinsky PF, Prorok PC, Kramer BJ.

N Engl J Med. 2017 Jun 15;376(24):2402. doi: 10.1056/NEJMc1705480. No abstract available.

PMID:
28614680
5.

Data sharing in clinical trials: An experience with two large cancer screening trials.

Zhu CS, Pinsky PF, Moler JE, Kukwa A, Mabie J, Rathmell JM, Riley T, Prorok PC, Berg CD.

PLoS Med. 2017 May 23;14(5):e1002304. doi: 10.1371/journal.pmed.1002304. eCollection 2017 May.

6.

Prostate Cancer Screening - A Perspective on the Current State of the Evidence.

Pinsky PF, Prorok PC, Kramer BS.

N Engl J Med. 2017 Mar 30;376(13):1285-1289. doi: 10.1056/NEJMsb1616281. No abstract available.

PMID:
28355509
7.

Breast-Cancer Tumor Size and Screening Effectiveness.

Welch HG, Prorok PC, Kramer BS.

N Engl J Med. 2017 Jan 5;376(1):94-5. doi: 10.1056/NEJMc1614282. No abstract available.

8.

Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.

Pinsky PF, Prorok PC, Yu K, Kramer BS, Black A, Gohagan JK, Crawford ED, Grubb RL, Andriole GL.

Cancer. 2017 Feb 15;123(4):592-599. doi: 10.1002/cncr.30474. Epub 2016 Dec 1.

9.

Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up.

Pinsky PF, Yu K, Kramer BS, Black A, Buys SS, Partridge E, Gohagan J, Berg CD, Prorok PC.

Gynecol Oncol. 2016 Nov;143(2):270-275. doi: 10.1016/j.ygyno.2016.08.334. Epub 2016 Sep 9.

10.

Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness.

Welch HG, Prorok PC, O'Malley AJ, Kramer BS.

N Engl J Med. 2016 Oct 13;375(15):1438-1447.

11.

Active follow-up versus passive linkage with cancer registries for case ascertainment in a cohort.

Pinsky PF, Yu K, Black A, Huang WY, Prorok PC.

Cancer Epidemiol. 2016 Dec;45:26-31. doi: 10.1016/j.canep.2016.09.003. Epub 2016 Sep 26.

12.

PLCO: Evolution of an Epidemiologic Resource and Opportunities for Future Studies.

Black A, Huang WY, Wright P, Riley T, Mabie J, Mathew S, Ragard L, Hermansen S, Yu K, Pinsky P, Prorok PC, Freedman ND, Hoover RN.

Rev Recent Clin Trials. 2015;10(3):238-45. Review.

PMID:
26435289
13.

Managing Multi-Center Recruitment in the PLCO Cancer Screening Trial.

Gohagan JK, Broski K, Gren LH, Fouad MN, Higgins D, Lappe K, Ogden S, Shambaugh V, Pinsky PF, O'Brien B, Yurgalevich S, Riley T, Wright P, Prorok PC.

Rev Recent Clin Trials. 2015;10(3):187-93. Review.

PMID:
26435288
14.

Study designs for determining and comparing sensitivities of disease screening tests.

Prorok PC, Kramer BS, Miller AB.

J Med Screen. 2015 Dec;22(4):213-20. doi: 10.1177/0969141315600003. Epub 2015 Sep 22.

PMID:
26396138
15.

Building Successful Relationships in the PLCO Cancer Screening Trial.

Marcus PM, Broski KG, Buys SS, Childs J, Church TR, Gohagan JK, Gren LH, Higgins D, Jaggi R, Jenkins V, Johnson CC, Lappe K, O'Brien B, Ogden SL, Prorok PC, Reding D, Shambaugh V, Yokochi LA, Yurgalevitch S.

Rev Recent Clin Trials. 2015;10(3):181-6. Review.

16.

Changes in and Impact of the Death Review Process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

Miller AB, Feld R, Fontana R, Gohagan JK, Jatoi I, Lawrence W Jr, Miller A, ProroK PC, Rajput A, Sherman M, Welch G, Wright P, Yurgalevitch S, Albertsen P.

Rev Recent Clin Trials. 2015;10(3):206-11. Review.

PMID:
26238119
17.

Comprehensive Quality Management (CQM) in the PLCO Trial.

Gohagan JK, O'Brien B, Hasson MA, Umbel KD, Bridgeman B, Kramer BS, Reding D, Gren L, Wright P, Riley T, Prorok PC.

Rev Recent Clin Trials. 2015;10(3):223-32.

PMID:
26238118
18.

Data Processing and Analytic Support in the PLCO Cancer Screening Trial.

Mabie J, Riley T, Marcus PM, Black A, Rozjabek H, Yu K, Young M, Austin J, Rathmell J, Williams C, Prorok PC.

Rev Recent Clin Trials. 2015;10(3):233-7. Review.

PMID:
26238116
19.

The PLCO Cancer Screening Trial: Background, Goals, Organization, Operations, Results.

Gohagan JK, Prorok PC, Greenwald P, Kramer BS.

Rev Recent Clin Trials. 2015;10(3):173-80. Review.

PMID:
26238115
20.

Quantification of length-bias in screening trials with covariate-dependent test sensitivity.

Heltshe SL, Kafadar K, Prorok PC.

Biom J. 2015 Sep;57(5):777-96. doi: 10.1002/bimj.201400152. Epub 2015 May 15.

PMID:
25980962

Supplemental Content

Loading ...
Support Center